



Express Mail No.: EV 841 454 793 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ternansky et al.

Confirmation No.: 8174

Application No.: 10/722,843

Group Art Unit: 1654

Filed: November 25, 2003

Examiner: Cordero Garcia, Marcela M.

For: PEPTIDES WHICH TARGET TUMOR AND
ENDOTHELIAL CELLS, COMPOSITIONS AND
USES THEREOF

Attorney Docket No.: 9715-024-999
(formerly: 34433/US/4/AMP/SKS)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A22, B01 and C01-C112 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references B01 and C01-C112 are submitted herewith. Copies of references A01-A22 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.


Respectfully submitted,

Date: August 11, 2006


Adriane M. Antler 52,605
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosure



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

9715-024-999

APPLICATION NO.

10/722,843

APPLICANT

Ternansky et al.

FILING DATE

November 25, 2003

ART UNIT

1654

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|----------------------|-----|-----------------|----------|-----------------------|---------------------------------------------------------------------------------|
| | A01 | 3,845,770 | 11/05/74 | Theeuwes et al. | |
| | A02 | 3,916,899 | 11/04/75 | Theeuwes et al. | |
| | A03 | 4,440,788 | 04/03/84 | Terayama et al. | |
| | A04 | 4,683,202 | 07/28/87 | Mullis | |
| | A05 | 4,765,539 | 08/23/88 | Noakes et al. | |
| | A06 | 5,112,598 | 05/12/92 | Biesalski | |
| | A07 | 5,443,816 | 08/22/95 | Zamora et al. | |
| | A08 | 5,556,611 | 09/17/96 | Biesalski | |
| | A09 | 5,561,220 | 10/01/96 | Dean et al. | |
| | A10 | 5,567,408 | 10/22/96 | Zamora | |
| | A11 | 5,618,513 | 04/08/97 | Srinivasan | |
| | A12 | 5,627,286 | 05/16/97 | Ramalingam et al. | |
| | A13 | 5,639,725 | 06/17/97 | O'Reilly et al. | |
| | A14 | 5,698,155 | 12/16/97 | Grosswald et al. | |
| | A15 | 5,950,619 | 09/14/99 | van der Linden et al. | |
| | A16 | 5,954,047 | 09/21/99 | Armer et al. | |
| | A17 | 5,970,974 | 10/26/99 | van der Linden et al. | |
| | A18 | 5,994,309 | 07/25/97 | Mazar et al. | |
| | A19 | 6,001,965 | 12/14/99 | Livant | |
| | A20 | 6,225,284 | 05/01/01 | Albert et al. | |
| | A21 | US 2002/0151501 | 10/17/02 | Bowers et al. | |
| | A22 | US 2004/0162239 | 08/19/04 | Ternansky et al. | |

FOREIGN PATENT DOCUMENTS

| | | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|--|-----|-----------------------------------------------------------------------------|----------|--------------------|---------------------------------------------------------------------------------|---|
| | B01 | WO 98/30538 | 07/16/98 | Kaneka Corporation | | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|----------------------------------------------------------------------------|-----------------------------------------|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 9715-024-999 | APPLICATION NO. 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE November 25, 2003 | ART UNIT 1654 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | C01 | ABOAGYE et al., "Use of positron emission tomography in anticancer drug development," Invest. New Drugs 2003, 21(2):169-181. | |
| | C02 | ADELMAN et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," DNA 1983, 2:183-193. | |
| | C03 | AKIYAMA et al., "Fibronectin and integrins in invasion and metastasis," Cancer Metastasis Rev. 1995, 14(3):173-189. | |
| | C04 | ALDERMAN, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," Int. J. Pharm. Tech. & Prod. Mfr., 1984, 5(3) 1-9. | |
| | C05 | ALMQUIST et al., "Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme," J. Med. Chem., 1980, 23: 1392-1398. | |
| | C06 | BALDARI et al., "A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae," EMBO J., 1987, 6: 229-234. | |
| | C07 | BAMBA et al., "Release Mechanisms in Gelforming Sustained Release Preparations," Int. J. Pharm., 1979, 2, 307 | |
| | C08 | BEAUCAGE et al., "Deoxynucleoside Phosphoramidites-New Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Lett., 1981, 22:1859. | |
| | C09 | BENJAMIN et al., "Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal," J. Clin. Invest., 1999, 103:159-165. | |
| | C10 | BLOOD et al., "Tumor interactions with the vasculature: angiogenesis and tumor metastasis," Biochem. Biophys. Acta., 1990, 1032: 89-118. | |
| | C11 | BOKEL, "Integrins in development: moving on, responding to, and sticking to the extracellular matrix," Dev. Cell," 2002, 3(3):311-321. | |
| | C12 | BORGSTROM et al., "Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo," Prostate, 1998, 35:1-10. | |
| | C13 | BORNSTEIN et al., "Matricellular proteins: extracellular modulators of cell function," Curr. Opin. Cell Biol. 2002, 14(5):608-616. | |
| | C14 | BROOKS et al. "Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity," Cell, 1998, 92: 391-400. | |
| | C15 | BRUCHEZ et al., "Semiconductor Nanocrystals as Fluorescent Biological Labels," Science, 1998, 281: 2013-2016. | |
| | C16 | CHAMBERS et al., "Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase," Canc. Res., 1995, 55:1578-1585. | |
| | C17 | CHAN et al., "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection," Science, 1998, 281: 2016-2018. | |
| | C18 | CHOREV et al., "Partially modified retro-inverso-enkephalinamides: topochemical long-acting analogs in vitro and in vivo," Science, 1979, 204: 1210-1212. | |
| | C19 | COOPER et al., "The role of alpha(v)beta(3) in prostate cancer progression," Neoplasia 2002, 4(3): 191-194. | |
| | C20 | CROWLEY et al., "Prevention of Metastasis by Inhibition of the Urokinase Receptor," Proc. Natl. Acad. Sci. USA, 1993, 90: 5021-5025. | |
| | C21 | DAMIANO, "Integrins as novel drug targets for overcoming innate drug resistance," Curr. Cancer Drug Targets 2002, 2(1):37-43. | |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

| | | |
|----------------------------------------------------------------------------|-------------------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 9715-024-999 | 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE | ART UNIT |
| | November 25, 2003 | 1654 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | C22 | DURING et al., "Controlled Release of Dopamine from Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol., 1989, 25:351. | |
| | C23 | EDGE et al., "Total synthesis of a human leukocyte interferon gene," Nature 1981, 292:756. | |
| | C24 | FELDING-HABERMANN, "Integrin activation controls metastasis in human breast cancer," Proc. Natl. Acad. Sci. USA 2001, 98(4):1853-1858. | |
| | C25 | FELDING-HABERMANN, "Integrin adhesion receptors in tumor metastasis," Clin. Exp. Metastasis 2003, 20(3): 203-213. | |
| | C26 | FOLKMAN, "Angiogenesis inhibitors generated by tumors," Mol. Med., 1995, 1(2): 120-122. | |
| | C27 | FOLKMAN, "Anti-angiogenesis: new concept for therapy of solid tumors," Ann. Surg., 1972, 175: 409-416. | |
| | C28 | FOLKMAN, "The influence of angiogenesis research on management of patients with breast cancer," Breast Cancer Res. Treat., 1995, 36(2): 109-118. | |
| | C29 | GEIGER et al., "Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk," Nat. Rev. Mol. Cell Biol. 2001, 2(11):793-805. | |
| | C30 | GIANNIS et al., "Peptidomimetics in Drug Design," Adv. in Drug Res., 1997, 29: 1-78. | |
| | C31 | GLASER et al., "Applications of positron-emitting halogens in PET oncology," Int. J. Oncol. 2003, 22(2):253-267. | |
| | C32 | GLUZMAN, "SV40-transformed simian cells support the replication of early SV40 mutants," Cell, 1981, 23:175-182. | |
| | C33 | GOODSON, Medical Applications of Controlled Release, Vol. 2, Chapt. 6, 115-138 (1984). | |
| | C34 | GORELIK et al., "Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity," J. Nat'l. Canc. Inst. 1980, 65:1257-1264. | |
| | C35 | GORELIK et al., "Host's immune state and kinetics of local tumor growth control--progression of postoperative lung metastasis," Rec. Results Canc. Res. 1980, 75:20-28. | |
| | C36 | HANAHAN et al., "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis," Cell 1996, 86(3): 353-364. | |
| | C37 | HERSCHMAN, "Molecular Imaging: Looking at Problems, Seeing Solutions," Science 2003, 302, (5645): 605-608. | |
| | C38 | HILGARD et al., "Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL)," Br. J. Cancer 1977, 35:78-86. | |
| | C39 | HOLLADAY et al., "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres," Tetrahedron Lett. 1983, 24:4401. | |
| | C40 | HOOD et al., "Role of integrins in cell invasion and migration," Nat. Rev. Cancer 2002, 2(2): 91-100 | |
| | C41 | HOWARD et al., "Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficit," J. Neurosurg. 1989, 71:105. | |
| | C42 | HRUBY, "Conformational and topographical considerations in the design of biologically active peptides," Biopolymers 1993, 33: 1073-1082. | |
| | C43 | HRUBY, "Conformational Restrictions of Biologically Active Peptides Via amino Acid Side Chain Groups," Life Sci. 1982, 4:189-199. | |
| | C44 | ISAKOV et al., "An immune response against the alloantigens of the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts," Invasion Metas. 1982, 2:12-32. | |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|----------------------------------------------------------------------------|-----------------------------------------|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 9715-024-999 | APPLICATION NO. 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE November 25, 2003 | ART UNIT 1654 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | C45 | JAY, "Chemical synthesis of a biologically active gene for human immune interferon-gamma. Prospect for site-specific mutagenesis and structure- function studies," J. Biol. Chem. 1984, 259:6311. | |
| | C46 | JENNINGS-WHITE et al., "Synthesis of Ketomethylene Analogs of Dipeptides," Tetrahedron Letters, 1982, 23:2533. | |
| | C47 | KAUFMAN et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian," EMBO J. 1987, 6:187-195. | |
| | C48 | KEMPERMAN et al., "The role of integrins and integrin activation in liver metastasis," Invasion Metastasis 1994-95, 14(1-6):98-108. | |
| | C49 | KERR et al., "The alpha v integrin antagonists as novel anticancer agents: an update," Expert Opin. Investig. Drugs 2002, 11(12):1765-1774. | |
| | C50 | KIM et al., "Regulation of Angiogenesis in Vivo by Ligation of Integrin 5B1 with the Central Cell-Binding Domain of Fibronectin," Am. J. Pathol. 2000, 156(4):1345-1362. | |
| | C51 | KLEINMAN et al., "Basement membrane complexes with biological activity," Biochemistry 1986, 25: 312-318. | |
| | C52 | KUMAR, "Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis," Curr. Drug. Targets 2003, 4(2):123-131. | |
| | C53 | KURJAN et al. "Structure of a yeast pheromone gene (MF alpha): a putative alpha-factor precursor contains four tandem copies of mature alpha-factor," Cell 1982, 30:933-943 | |
| | C54 | LABAT-ROBERT, "Fibronectin in Malignancy," Semin. Cancer Biol. 2002, 12(3):187-195. | |
| | C55 | LANGER, "New methods of drug delivery," Science 1990, 249:1527-1533. | |
| | C56 | LANGER et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol Chem. 1983, 23:61. | |
| | C57 | LEVY et al., "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," Science 1985 228: 190. | |
| | C58 | LI et al., "Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates," Biomacromolecules 2003, 4:1055-1067. | |
| | C59 | LIU et al., "Antiangiogenic therapy," Semin. Oncol. 2002, 29 (3 Suppl. 11): 96-103. | |
| | C60 | LOHR et al., "Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas," Pancreas 1996, 12(3):248-259. | |
| | C61 | LUCKOW et al., "High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors," Virology 1989, 170:31-39. | |
| | C62 | MALAVE et al., "Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice," J. Nat'l. Canc. Inst. 1979, 62:83-88. | |
| | C63 | MATTEUCCI et al., "Synthesis of Deoxyoligonucleodites on a Polymer Support," J. Am. Chem. Soc. 1981, 103:3185. | |
| | C64 | MAXAM et al., "Sequencing end-labeled DNA with base-specific chemical cleavages," Meth. Enzymol. 1980, 65:499-560. | |
| | C65 | MERAJVER et al., "Cooper Depletion as and Anti-Angiogenic Strategy in HER2-neu Transgenic," Proceedings of Special AACR Conference on Angiogenesis and Cancer 1998, Abstract #B-11, January 22-24. | |
| | C66 | MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Terapeptide," J. Amer. Chem. Soc. 1963, 85: 2149-2154. | |
| | C67 | MESSING et al., "A system for shotgun DNA sequencing," Nucleic Acids Res. 1981, 9:309. | |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

| | | |
|----------------------------------------------------------------------------|-------------------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 9715-024-999 | 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE | ART UNIT |
| | November 25, 2003 | 1654 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | C68 | METZNER et al., "Evidence of the involvement of phosphatidylinositol 3-kinase in the migration, actin stress fiber formation, and alpha v beta 3-integrin- mediated adherence of human melanoma cells," J. Invest. Dermatol. 1996, 107(4): 597-602. | |
| | C69 | MILLAUER et al., "Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo," Cancer Res. 1996, 56: 1615-1620. | |
| | C70 | MIN et al., "Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice," Cancer Res. 1996, 56: 2428-2433. | |
| | C71 | MOORE et al., "Design and pharmacology of peptide mimetics," Adv. in Pharmacol. 1995, 33: 91-141. | |
| | C72 | NAMBIAR et al., "Total synthesis and cloning of a gene coding for the ribonuclease S protein," Science 1984, 223:1299. | |
| | C73 | NGUYEN et al., "Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane," Microvascular Res. 1994, 47:31 40. | |
| | C74 | NIP et al., "The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis," Cancer Metastasis Rev. 1995, 14(3): 241-252. | |
| | C75 | O'BRIEN et al., "Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation," Exp. Cell Res. 1996, 224(1): 208-213. | |
| | C76 | O'REILLY et al. "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 1994, 79:315-328. | |
| | C77 | O'REILLY et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell 1997, 88:277-285. | |
| | C78 | ODEDRA et al., "Low molecular weight angiogenesis factors," Pharmac. Ther. 1991, 49:111-124. | |
| | C79 | OLSON et al., "Concepts and progress in the development of peptide mimetics," J. Med. Chem. 1993, 36: 3039. | |
| | C80 | PARISH et al., "A basement-membrane permeability assay which correlates with the metastatic potential of tumor cells," Int. J. Cancer 1992, 52: 378-383. | |
| | C81 | PASSANITI et al., A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992 67:519-528. | |
| | C82 | PECHEUR et al., "Integrin alpha v beta 3 expression confers on tumor cells a greater propensity to metastasize to bone," FASEB J. 2002, 16(10): 1266-1268. | |
| | C83 | PLATTEN et al., "Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression," Biochem. Biophys. Commun. 2000, 268(2): 607-611. | |
| | C84 | RABB et al., "Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney," Am. J. Nephrol. 1996, 16(5):402-408. | |
| | C85 | RABBANI et al., "Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)," Int. J. Cancer 1995, 63: 840-845. | |
| | C86 | RALEIGH et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," British J. Cancer, 1999, 80 Suppl. 2, 96. | |
| | C87 | RUOSLAHTI, "Fibronectin and its alpha 5 beta 1 integrin receptor in malignancy," Invasion Metastasis 1994; 14(1-6): 87-97. | |
| | C88 | RUST et al., "The Promise of Integrins as Effective Targets for Anticancer Agents," J. Biomed. Biotechnol. 2002, 2(3): 124-130. | |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

| | | |
|----------------------------------------------------------------------------|--------------------------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 9715-024-999 | 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE | ART UNIT |
| | November 25, 2003 | 1654 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | C89 | SANGER, "DNA sequencing with chain-terminating inhibitors," Proc. Natl. Acad. Sci. USA 1977, 74:5463-5467. | |
| | C90 | SAUDEK et al., "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J Med. 1989 321:574-579. | |
| | C91 | SCHNAPER et al., "Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways," J. Cell. Physiol. 1995, 165: 107-118. | |
| | C92 | SCHULTZ et al., "Expression and Secretion in Yeast of a 400-kDA Envelope Glycoprotein Derived from Epstein-Barr Virus," Gene 1987, 54:113-123. | |
| | C93 | SEFTON, "Implantable pumps," CRC Crit. Ref. Biomed. Eng. 1987, 14:201-240. | |
| | C94 | SHOCKLEY et al., "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," Ann. N.Y. Acad. Sci., 1991, 617:367-382. | |
| | C95 | SMITH et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Mol. Cell Biol., 1983, 3:2156-2165. | |
| | C96 | SPATOLA, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," B. Weinstein, (eds.), Marcel Dekker, New York, 1983, pp. 267-357. | |
| | C97 | SPATOLA et al., "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates," Life Sci., 1986, 38:1243-1249. | |
| | C98 | STOELTZING et al., "Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice," Int. J. Cancer 2003, 104(4):496-503. | |
| | C99 | STUPACK et al., "Get a ligand, get a life: integrins, signaling and cell survival," J. Cell Sci. 2002, 115: 3729-38. | |
| | C100 | TALMADGE et al., "Enhanced Metastatic Potential of Tumor Cells Harvested from Spontaneous Metastases of Heterogeneous Murine Tumors J. Nat'l. Canc. Inst. 1982, 69:975-980. | |
| | C101 | TANI et al., "Expression level of integrin alpha 5 on tumor cells affects the rate of metastasis to the kidney," Br. J. Cancer 2003, 88(2): 327-333. | |
| | C102 | THAKUR et al., "Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs," J. Lab. Clin. Med. 1977, 89:217-228. | |
| | C103 | TREAT et al., in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez Berestein and Fidler (eds.), Liss, New York, pp.353-365 (1989). | |
| | C104 | TUCKER, "Inhibitors of integrins," Curr. Opin. Pharmacol. 2002, 2(4): 394-402. | |
| | C105 | VAN DE WIELE et al., "Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging," Eur. J. Nucl. Med. Mol. Imaging 2002, 29(5): 699-709. | |
| | C106 | VARNER et al., "Tumor angiogenesis and the role of vascular cell integrin alphavbeta3," Import Adv. Oncol. 1996, 69-87. | |
| | C107 | VERMA et al., "Osmotically Controlled Oral Drug Delivery," Drug Dev. Ind. Pharm., 2000, 26:695-708. | |
| | C108 | VERSCHOYLE et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats following Oral Dosing or Aerosol Inhalation," Br. J. Cancer 1999, 80 Suppl. 2: 96. | |
| | C109 | VOLPERT et al., "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," J. Clin. Invest. 1996, 98: 671-679. | |
| | C110 | WILEY et al., "Peptidomimetics Derived from Natural Products," Med. Res. Rev. 1993, 13: 327-384. | |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

| | | |
|----------------------------------------------------------------------------|-----------------------------------------|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 9715-024-999 | APPLICATION NO. 10/722,843 |
| | APPLICANT Ternansky et al. | |
| | FILING DATE November 25, 2003 | ART UNIT 1654 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
| | C111 | XING et al., "Overexpression of Urokinase Receptor in Breast Int. J. Cancer 1996, 67: 423-429. | |
| | C112 | ZOLLER et al., "Oligonucleotide-Directed Mutagenesis using M13-Derived Vectors: an Efficient and General Procedure for the Production of Point Mutations in any Fragment of DNA," Nucleic Acids Res. 1982, 10:6487-6500. | |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |